The -172A>G polymorphism in ADAM17 promoter region enhances its binding to EGR1 and confers susceptibility to sepsis progression

Yiming Shao
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Wenying Zhang
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Tian Zhao
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Furong Lu
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Yuan Hong
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Lizhen Liu
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Yujie Cai
Institute of Neurology, Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University

Ning Wei
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

HongXiao Cheng
The Intensive Care Unit, The Second Affiliated Hospital of Guangdong Medical University

Feng Chen
Institute of Neurology, Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University

Junbing He
The Intensive Care Unit, Jieyang Affiliated Hospital, SunYat-sen University

Lili Cui (cuilili@gdmu.edu.cn)
Institute of Neurology, Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University

Research

Keywords: ADAM17, EGR1, Polymorphism, Sepsis, inflammation

DOI: https://doi.org/10.21203/rs.3.rs-73158/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: A disintegrin and metalloproteinase 17 (ADAM17) is a proteolytic cleaving protein with a crucial function in inflammatory responses, especially sepsis. But the clear role of ADAM17 in sepsis and the underlying mechanism remained unknown. In this study, we aim to determine the clinical relevance of the ADAM17 rs12692386 (-172A>G) promoter polymorphism in sepsis progression and to further explore the effect and mechanism of the early growth response 1 (EGR1) /ADAM17 pathway in the inflammatory process following sepsis.

Methods: A case-control study with a total of 903 sepsis patients and 1150 controls were enrolled to determine the association of ADAM17 -172A>G polymorphism with sepsis. The transcription factor binding to the promoter region of ADAM17 gene was predicted by bioinformatics analysis and verified by Chromatin Immunoprecipitation (ChIP) and luciferase assays. Quantitative real-time PCR and Western blot were performed to detect EGR1 and ADAM17 expression. Cytokine production was detected by enzyme-linked immunosorbent assay. The effect of EGR1/ADAM17 pathway on sepsis-induced inflammatory responses was evaluated in EGR1-silenced cells and endotoxemia mouse model.

Results: Patients with sepsis subtype exhibited significantly lower frequencies of the -172AG/GG genotypes compared to those with severe sepsis (29.3% vs. 45.9%, \( P = 0.0002 \)) or septic shock (29.3% vs. 42.4%, \( P = 0.0032 \)). The frequency of -172G allele in the 28-day non-surviving patients was significantly higher than that in the surviving patients (29.3% vs. 21.8%, \( P = 0.0188 \)). The results of in vitro lipopolysaccharide-stimulated and luciferase assays indicated that the −172 A-to-G variation could functionally upregulate promoter activity and transcription of ADAM17 gene via enhancing the binding affinity of its promoter region with the EGR1. The ChIP assay identified the direct interaction. Further studies demonstrated that the EGR1/ADAM17 intervention could significantly decrease the pro-inflammatory cytokine secretion in vitro and improve the survival and inflammatory response of sepsis mouse model.

Conclusions: These results provide evidence that the ADAM17 -172A>G polymorphism can functionally enhance ADAM17 expression and promote sepsis-induced inflammatory responses via the EGR1/ADAM17 pathway, which ultimately promote sepsis progression and poor prognosis.

Introduction

It has been demonstrated that inappropriate systemic inflammatory responses results in poor prognosis in critically ill patients with sepsis [1]. Recent epidemiological studies have demonstrated that several genetic variations within genes encoding inflammation-related factors play a crucial role in the susceptibility to and progression of sepsis [2]. Diagnostic strategies based on targeted gene sequencing and therapies directed against genetic polymorphisms might improve the prognosis of sepsis patients.

A disintegrin and metalloproteinase 17 (ADAM17), a member of the ADAM family, is involved in the shedding of more than 80 cellular substrates, including tumor necrosis factor-alpha (TNF-\( \alpha \)), interleukin-6 receptor (IL-6R) and vascular cell adhesion molecule-1 (VCAM-1), and the initiation of several inflammatory signaling pathways that are hypothesized to play critical roles in sepsis [3-8]. Several lines of evidence indicate that ADAM17 is highly expressed in sepsis patients and animal models of sepsis, which is markedly associated with organ dysfunction and mortality [9-11]. The inhibition or genomic deletion of ADAM17 contributes to bacterial clearance and a decreased inflammatory response and offers mice a survival benefit following sepsis [12-14], and these findings indicate an important role of ADAM17 in the pathogenesis of sepsis. The human ADAM17 gene is located on chromosome 2 and contains 19 exons. Accumulating evidence demonstrates that single-nucleotide polymorphisms (SNPs) in the ADAM17 gene are associated with risk for various inflammation-related diseases, such as ischemic stroke, Kawasaki disease and cardiovascular death [15-17]. Our previous study revealed, for the first time that ADAM17 -172A>G may act as a functional SNP involved in sepsis progression [11]. However, the mechanism through which this SNP affects ADAM17 expression and sepsis progression remains unknown, and a larger and independent validation cohort study is needed to verify our results.

EGR1 is a transcription factor involved in the regulation of diverse cellular functions by regulating the transcription of a wide array of downstream genes [18, 19]. This transcription factor can be upregulated by cytokines, hypoxia, vascular injury and septic shock [20-23]. In an LPS-induced endotoxemia mouse model, EGR-1 contributes to the sustainable appearance of inflammatory mediators in the kidneys and lungs [24], and EGR1 could be induced to rise significantly in sepsis within 30 minutes [25]. Additionally, EGR1 is involved in the modulation of the ERK, JNK and p38 MAPK pathways and the production of inflammatory cytokines [26, 27]. A bioinformatics analysis revealed a conserved putative transcription factor-binding site for EGR1 in the 5'-untranslated region (5'-UTR)
of human ADAM17. However, the specific role of the -172A>G polymorphism and EGR1 in the regulation of ADAM17 transcriptional expression and sepsis remains unclear. Thus, we expanded the previous studied samples and enrolled two additional populations to validate the clinical association of the -172A>G polymorphism with sepsis. Furthermore, functional in vitro and vivo assays were conducted to characterize the role of -172A>G and EGR1 in the modulation of inflammatory responses in sepsis by regulating ADAM17 gene transcription. The mechanistic characterization of this sepsis-associated functional polymorphism might provide new opportunities for the development of targeted treatments for sepsis.

Methods

Study population

A total of 903 sepsis patients and 1,150 healthy individuals from three regions of China were recruited in this study between February 2013 and June 2018. There were 370 patients and 400 healthy controls included in our prior cohorts [11]. The patients were enrolled in the study if they met the following inclusion criteria: 1) the diagnosis of sepsis, severe sepsis, or septic shock was established by ICU senior attending physicians according to the International Sepsis Definitions Conference [28]; 2) the patients were older than 18 years of age and belonged to the Chinese Han population; and 3) the patients had a probability of survival greater than 24 hours. Patients were excluded from this study if they had diabetes, malignant tumors, human immunodeficiency virus, or autoimmune diseases or were pregnant, readmitted to a hospital or receiving immunosuppressive therapy, corticosteroid therapy or chemoradiotherapy. The sepsis, severe sepsis or septic shock is the initial situation of the disease in the patients. The healthy controls, which were enrolled at the health examination center at each hospital, had no history of sepsis, no recent acute illness and no chronic illness, such as autoimmune diseases, diabetes, cancer and major cardiac, renal, hepatic, and endocrinological disorders. The healthy controls also belonged to the Chinese Han population, and their healthy status was determined by reviewing the medical examination reports and questioning the participants. The age, sex, source of infection, cause of infection, pathogenic bacteria, and Acute Physiology and Chronic Health Evaluation (APACHE) II results of each patient were documented, and blood samples were collected within 12 hours after the diagnosis of sepsis, severe sepsis, or septic shock was established. The survival of all the patients was observed for a 28-day period. The participants’ confidentiality was preserved according to the guidelines for studies of human subjects. This study was approved by the Ethics Committees of the participating hospitals, and written informed consent was signed by all enrolled subjects or their families prior to enrollment.

DNA isolation and genotyping

Genomic DNA was isolated from Peripheral blood mononuclear cells (PBMCs) using the TIANamp Blood DNA Kit (TianGen Biotech, Beijing, China) according to the vendor’s recommendations. The ADAM17 -172A>G polymorphism was genotyped using the ABI PRISM® SNaPshot™ Multiplex Kit (Applied Biosystems, Carlsbad, CA, USA). The sequences of the forward and reverse primers were 5’-GGCCCTAGCCCTCAATCCTCTT-3’ and 5’-TTTTTTTGGTAACGCCACCTG -CCTTC-3’, respectively. The obtained data were analyzed using Gene Mapper 4.1 (Applied Biosystems, Foster City, CA, USA).

Mononuclear cell isolation and cell culture

PBMCs were isolated from the blood samples collected from sepsis patients and healthy individuals by density gradient centrifugation using Lymphoprep™ (Axis-Shield PoCAS, Oslo, Norway). The PBMCs from the 18 healthy individuals were randomly selected for in vitro LPS stimulation experiments. Mouse leukemia cells of monocyte macrophage (RAW264.7 cells), human umbilical vascular endothelial cells (HUVECs) and human embryonic kidney cells (HEK293T) were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were grown at 37 °C with 5% CO₂ in DMEM or RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (Invitrogen, USA) and penicillin/streptomycin (Sigma-Aldrich, USA).

Plasmid or virus construction

Plasmids for the overexpression of human pCMV-EGR1 were obtained from Longqian Biotech (Shanghai, China). Transient transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s recommended protocol. The EGR1 adenovirus packages used for the overexpression or silencing experiments with HUVECs were designed and synthesized by Shanghai Genechem Co., Ltd. (China). The expression of EGR1 infection was detected by Western blotting, quantitative real-time PCR (qRT-PCR) and fluorescence.
Mice

C57BL/6 mice (8-12 weeks, males and females in half) were purchased from Guangdong Laboratory Animal Center (Guangzhou, China). The mice used for the experiments in this study were bred and maintained under conventional housing conditions in our animal facility. The animal experimental protocols were reviewed and approved by the Ethics Committee of Affiliated Hospital of Guangdong Medical University, China. EGR1 antisense oligonucleotide (As-ODN) (5’-TACCGTCGCCGTTTC-3’) was constructed to inhibit EGR1 by targeting the corresponding DNA sequence. The EGR1 sense ODN (S-ODN) (5’-TCGTGCCGCTGCCAT-3’) was used as a negative control [29]. All ODNs were synthesized by Takara Biomedical Technology Co., Ltd. The mice were intraperitoneally injected with LPS (Escherichia coli O55:B5, Sigma-Aldrich, USA) at a dose of 10 mg/kg to establish the endotoxemia model. Blood was collected from the mice and centrifuged for measurement of the serum concentrations of TNF-α, IL-6 and IL-1β using each specific enzyme-linked immunosorbent assay (ELISA) kits. Lung and liver tissues were collected for the detection of ADAM17 and EGR1 mRNA expression. For the survival experiments, the mice were intraperitoneally injected with LPS (20 mg/kg) and monitored for 72 hours.

qRT-PCR and Western blot analysis

Total RNA from the PBMCs, cells or tissues was extracted using the TRIzol reagent (Invitrogen), and complementary DNA (cDNA) was synthesized from 1 μg of total pure RNA using the PrimeScript™ RT reagent kit with cDNA Eraser (Takara) in accordance to the manufacturer’s recommended protocol. The primer sequences used in this study were designed by Sangon Biotech (see Additional file 1). The protein concentrations were determined using the BCA protein assay kit (Thermo Fisher Scientific, USA). The following rabbit polyclonal antibodies were used: anti-ADAM17 (diluted at 1:1000, Abcam, UK), anti-EGR1 (1:1000, Abcam, UK), anti-SP1 (1:1000, Abcam, UK), anti-AP2α (1:500, Abcam, UK), and anti-β-actin antibody (1:2000, CST, USA).

Cytokine measurements

The concentrations of IL-1β, IL-6, and TNF-α in the supernatants obtained from cell culture medium or animal plasma were measured using each specific ELISA kits according to the manufacturer's instructions. The following ELISA kits were used: TNF-α, IL-6, and IL-1β (Boster Biological Technology, USA).

Flow cytometric analysis

Cell apoptosis was detected by flow cytometry using the Annexin V-PE/7-AAD Apoptosis Detection Kit (YEASEN Biotechnology, Shanghai, China) following the manufacturer's instructions. The cells were harvested, washed twice with ice-cold PBS, and resuspended to a density of 1×10^6 cells/mL in binding buffer. The cells were mixed with 5 μL of Annexin V-PE and 10 μL of 7-AAD and incubated at room temperature for 15 minutes. The cells were subsequently mixed with 400 μL of binding buffer and detected by flow cytometry.

Bioinformatics analysis

In order to predict the possible transcription factors that might bind to the promoter region of the ADAM17 gene, we submitted a 200-bp sequence around the -172 position in the ADAM17 gene promoter to the following three transcription factor prediction websites: http://tfbind.hgc.jp/, http://jaspar.genereg.net/cgi-bin/jaspar_db.pl, and http://gene regulation.com/pub/programs/alibaba2/index.html. The final set of transcription factors was obtained by combining the results obtained using these three software packages (see Additional file 2).

Luciferase plasmid constructs and luciferase reporter assay

The human ADAM17 promoter sequence carrying rs12692386 (A or G allele at position -172) was cloned into pGL3 luciferase reporter vectors (Promega, Madison, WI, USA). The primers F-5’-CTAGCAAAATAGGCTGTCC-3’ and R-5’-GCCGGGCCTTTCTTTATG-3’ were used to obtain the promoter gene fragment of ADAM17 by PCR amplification, and the pGL3-ADAM17-A/G plasmids were ultimately obtained. HEK293T cells were cotransfected with ADAM17 promoter reporter vectors and the transcription factor-overexpressing plasmid by Lipofectamine 2000 (Invitrogen, USA). The level of luciferase activity was assayed using the dual-luciferase reporter assay system (Promega, USA). Firefly luciferase activity was normalized to Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP)-qPCR
ChIP assays were performed the standard protocol with some modifications. ChIP coupled with quantitative PCR was used to investigate the protein-DNA interactions at binding sites in the ADAM17 gene. Briefly, chromatin was cross-linked with transcription factors, sheared into fragments (100–750 bp) by sonication and immunoprecipitated using antibody against EGR1 (CST, USA). The recovered DNA was analyzed by PCR using primers flanking the putative transcription factor-binding sites as indicated. The primers used for PCR of the ChIP fragments were as follows: F-5’-CGTGGGCGGGCAAG-3’ and R-5’-GCAGGTGGCGTTACCAA -AGG-3’. The PCR program was 95 °C for 30 seconds followed by 40 cycles of 95 °C for 5 seconds and 60 °C for 30 seconds.

Statistical analysis

The association between ADAM17 polymorphism and sepsis was determined using the Chi-squared test or Fisher's exact test, and the sample sizes were based on our previous experience. The Benjamini-Hochberg procedure for multiple testing correction was used to analyze the false discovery rate, and $P<0.05$ after Benjamini-Hochberg correction for multiple testing was considered significant. The survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. Analysis of clinical variables such as sex were analyzed by the Chi-squared test. Image J software was used for densitometry quantification of the Western blot bands. The values are shown as the mean ± standard deviation (SD). The expression of ADAM17 and EGR1, and cytokine levels in the independent groups were compared using the non-parametric Mann-Whitney U test (two-tailed). The statistical analyses were performed using SPSS 19.0 (IBM, NY, USA) or GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA), and $P$ value less than 0.05 was considered statistically significant. Additional details are provided in the figure legends, where appropriate.

Results

Study population and clinical characteristics

The Consolidated Standards of Reporting Trials (CONSORT) flowchart of this study is shown in Additional file 3. A total of 903 sepsis patients (mean age: 60.9±17.1 years; 31.7% female) and 1,150 healthy individuals (mean age: 48.1±15.2 years; 38.1% female) were enrolled in this study between February 2013 and June 2018. The clinical characteristics of the enrolled subjects (903 sepsis patients) are presented in Table 1. The 903 septic cases encompassed 181 patients with sepsis subtypes (20.0%), 368 patients with severe sepsis (40.8%), and 354 patients with septic shock (39.2%). The most common source of infection was respiratory tract infection (576/903, 63.8%), followed by Abdominal infection (128/903, 14.2%). The main pathogens identified in this study were *Acinetobacterbaumannii* (237/903, 26.2%), *P. aeruginosa* (109/903, 12.1%), *Escherichia coli* (97/903, 10.7%), *Staphylococcus aureus* (79/903, 8.7%), and *Klebsiella pneumoniae* (61/903, 6.8%). Gram-positive and gram-negative infections accounted for 12.1% (109/903) and 32.8% (296/903) of all the infections, respectively, and patients with polymicrobial infections comprised 12.1% (109/903) of all the patients.

Effect of ADAM17 genetic variations on susceptibility to sepsis development

A total of 903 sepsis cases were separated according to the severity of sepsis into three subgroups, namely the sepsis subtype, severe sepsis and septic shock subgroups, to evaluate the association of the ADAM17 -172A>G polymorphism with sepsis progression (Table 2). Our data showed that the frequencies of the AG/GG genotypes and G allele of rs12692386 in the sepsis subtype subgroup significantly differed from those in the severe sepsis subgroup (29.3% vs. 45.9%, $P=0.0005$ for genotype; 17.1% vs. 25.8%, $P=0.0039$ for allele) and septic shock subgroup (29.3% vs. 42.4%, $P=0.0032$ for genotype; 17.1% vs. 23.3%, $P=0.0193$ for allele). Additionally, our data showed no significant differences in genotype/allele frequencies of ADAM17 polymorphism between patients and healthy controls (all $P>0.05$) (Table 3). Besides, we separated the new studied subjects (533 sepsis patients and 750 healthy controls) enrolled from May 2016 to June 2018 were from the previously published cohort to validate the genetic effect of ADAM17 polymorphism on sepsis. As presented in Additional file 4 and 5, the data indicated that: 1) the frequencies of the AG/GG genotype of ADAM17 rs12692386 in the sepsis subtype subgroup differed from those in the severe sepsis & septic shock subgroups (P3=0.0197); 2) No statistically differences were observed between the sepsis cases and controls concerning the genotype/allele frequencies of the ADAM17 polymorphism (all $P>0.05$).

The 28-day ICU mortality was also analyzed to evaluate the effect of this ADAM17 SNP on the clinical outcome of sepsis patients. As presented in Table 4, the frequencies of non-survivors among the sepsis patients with the -172AG/GG genotypes and G allele were distinctly higher than those among patients with the AA genotype (50.7% vs. 39.3%, OR=0.630, 95% CI=0.444-0.894, $P=0.0188$) and A allele (29.3 % vs. 21.8 %, OR = 1.482, 95 % CI = 1.125-1.952, $P= 0.0188$). In addition, the Kaplan-Meier survival analysis indicated that
the 28-day survival in septic patients with -172AG/GG genotypes was much worse than in the AA genotype carriers (log-rank test 4.696, \( P=0.030 \)) (see Additional file 6).

Effect of ADAM17 SNP on expression of ADAM17 and proinflammatory cytokines

We divided 80 randomly selected sepsis cases into subgroups based on organ failure and the patients’ 28-day mortality, and statistically significant differences in ADAM17 expression were observed between the multiple organ dysfunction (MODS) and non-MODS subgroups (Fig. 1a). ADAM17 expression was decreased in the sepsis patients who survived during the 28-day period compared with the patients who did not survive (Fig. 1a). To confirm the impact of ADAM17 -172A>G variation on ADAM17 expression in vitro, PBMCs were isolated from 18 randomly selected healthy individuals and stimulated with LPS. As shown in Fig.1b, ADAM17 expression was significantly increased in LPS-stimulated PBMCs compared with the control PBMCs. Furthermore, PBMCs with -172AG/GG genotypes exhibited higher expression levels of ADAM17 than those carrying the AA genotype upon LPS stimulation (\( P = 0.008 \)), but these differences were not observed in the absence of LPS-stimulation (\( P > 0.05 \)). Additionally, the TNF-\( \alpha \) and IL-6 level were increased in PBMCs carrying the AG/GG genotypes compared to those with the AA genotype upon LPS stimulation (\( P = 0.0009 \) and \( P = 0.013 \), respectively) (Fig. 1d).

EGR1 expression is upregulated in sepsis and is associated with ADAM17

A bioinformatics analysis was used to predict that three transcription factors, namely, EGR1, specificity protein 1 (SP1) and TFAP2A (AP2\( \alpha \)), would bind to the -172A>G promoter region in an allele-specific manner (Fig. 2a). And we found that EGR1, but not SP1 and AP2\( \alpha \), was significantly increased in LPS-pretreated HUVECs, as well as ADAM17 (Fig. 2b-c). ADAM17 protein levels peak around 6 hours (Fig. 2d). Moreover, in the LPS stimulated HUVECs, EGR1 mRNA increases within 3 hours and reaches to a peak level at 6 hours, which in agreement with the trend found for ADAM17 expression in HUVECs (Fig. 2e). We further detect production of inflammatory cytokines TNF-\( \alpha \), IL-1\( \beta \) and IL-6 at each time point after LPS-stimulation in HUVECs. As presented in Figure 2f, our results show a significant increase in TNF-\( \alpha \), IL-1\( \beta \) and IL-6 at 6 hours, and the TNF-\( \alpha \) production exhibits a rapid growth within 2 hours and its peak around 6 hours, as well as ADAM17 mRNA expression. In addition, EGR1 mRNA expression was higher in sepsis patients than in healthy controls (\( P = 0.0015 \)) (Fig. 2g), as well as in LPS stimulated PBMCs isolated from healthy controls compared to the control group (\( P = 0.0056 \)) (Fig. 2h). We also evaluated the effect of ADAM17 genetic variation on expression of EGR1 transcription factor. As shown in Figure 2i, the sepsis patients with AG/GG genotypes exhibited significantly higher expression of EGR1 than those with AA genotype (\( P<0.0001 \)). Furthermore, PBMCs with -172AG/GG genotypes exhibited significantly higher expression of EGR1 than those with AA genotype under LPS stimulation \textit{in vitro} (\( P = 0.0005 \)) (Fig. 2j).

ADAM17 -172A>G polymorphism upregulates the ADAM17 gene expression via enhancing the binding affinity of its promoter region with the transcription factor EGR1

As shown in Figure 3a and 3b, ChIP-qPCR conducted with HUVECs showed that EGR1 bound to the promoter region of the ADAM17 gene. For the luciferase reporter assays, a 6307-bp ADAM17 promoter-luciferase reporter and the corresponding reporter with a single point mutation (A-to-G) on the ADAM17 rs12692386 site were constructed, and these constructs were cotransfected into HEK293T cells with pCMV-EGR1 (Fig. 3c). As shown in Fig. 3d, EGR1-overexpressing HEK293T cells transfected with pGL3-G exhibited higher luciferase activities than cells transfected with pGL3-A. We further investigated the impact of EGR1 on the regulation of ADAM17 expression in an LPS-induced HUVECs. The construction and efficiency of infection of EGR1 overexpressed and silent adenovirus were presented (see Additional file 7). EGR1-overexpressing or EGR1-silenced virus successfully infected HUVECs (Fig. 3e, g). The presence of EGR1 significantly increased ADAM17 expression in LPS-induced cells, whereas these effects were completely abrogated by EGR1 knockdown (Fig. 3f).

Effects of the EGR1/ADAM17 signaling pathway on proinflammatory cytokine secretion and apoptosis \textit{in vitro}

The concentrations of TNF-\( \alpha \), IL-1\( \beta \) and IL-6 in and the apoptosis rate of LPS-pretreated cells were then analyzed to confirm the impact of the EGR1/ADAM17 signaling pathway on sepsis. Our results showed that EGR1-silenced RAW264.7 cells displayed significantly lower expression levels of TNF-\( \alpha \) (31.5 ± 3.1 pg/mL, \( P=0.029 \)) and IL-6 (144.5 ± 33.1 pg/mL, \( P=0.029 \)) compared with the control cells (47.5 ± 2.1 pg/mL and 417.3 ± 1.4 pg/mL, respectively) upon LPS stimulation. Decreased expression of TNF-\( \alpha \) (17.3 ± 1.7 pg/mL, \( P=0.029 \)) and IL-1\( \beta \) (4.4 ± 2.9 pg/mL, \( P=0.029 \)) was also observed in LPS-stimulated EGR1-silenced HUVECs compared with
those in LPS-stimulated cells (30.7 ± 4.9 pg/mL and 15.7 ± 2.9 pg/mL, respectively) (Fig. 4a). In addition, the silencing of EGR1 through EGR1-RNAi infection significantly decreased the apoptotic rate of RAW264.7 cells upon LPS stimulation (Fig. 4b).

**EGR1 inhibition reduces the sepsis-induced inflammatory responses and improves the survival rate of endotoxemic mice**

Given the important role of EGR1 in the upregulation of ADAM17 expression in LPS-induced cells, we investigated whether EGR1 silencing is involved in the attenuation of the inflammatory response *in vivo*. ADAM17 gene expression was decreased in the lung and liver tissues of As-ODN-pretreated endotoxemia mice compared with those of LPS-treated control mice, and this effect was accompanied by the downregulation of endothelial cell injury factors, including ICAM1 and VCAM1 (Fig. 5b, c). In addition, As-ODN administration afforded mice a significant survival benefit following sepsis for 72 hours (Fig. 5d). Plasma levels of IL-1β (68.4 ± 16.3 pg/mL, \(P=0.026\)), IL-6 (761.5 ± 775.0 pg/ml, \(P=0.015\)), and TNF-α (199.5 ± 159.7 pg/ml, \(P=0.0411\)) in As-ODN-pretreated endotoxemia mice were significantly decreased compared with those in the LPS-treated control mice (102.50 ± 28.68 pg/ml, 2914.0 ± 1540.0 pg/ml, 458.8 ± 147.5 pg/ml, respectively) at 6 hours post-LPS injection (Fig. 5e).

**Discussion**

Convincing evidence demonstrates that ADAM17 SNPs play a crucial role in driving the inflammatory response during the course of inflammation-related diseases, which led us to focus on the relationship between genetic variations in ADAM17 and sepsis. In our previous study, a total of 370 cases and 400 controls was used to demonstrate the clinical relevance of five SNPs in the promoter region of ADAM17 in the susceptibility and progression of sepsis by showing that rs12692386 is a susceptibility locus for the development of sepsis and is potentially involved in the regulation of ADAM17 transcriptional expression [12]. To further verify this clinical phenomenon, we expanded the sample size and collected cases and controls from the other two regions from China. The sample collection time of the previous study was from February 2013 to April 2016, and continuously, we have collected 533 cases and 750 controls from 2016 to 2018. Before combined these two samples, the same statistical method was conducted to analyze the newly admitted subjects (case-control: 533-750). This result also demonstrated that patients with the ADAM17 -172AG/GG genotype exhibit a trend toward aggravated sepsis development from sepsis subtype to severe sepsis and septic shock (Additional file 4), which is consistent with our previous results. The ADAM17 -172GA/GG genotypes were found to be overrepresented in 28-day non-surviving sepsis patients compared to those in 28-day surviving sepsis patients, further validating the notion that the-172A>G is a statistically significant independent prognostic factor and may serve as a genetic marker for predicting the progression of sepsis in sepsis patients. In this study, we further explored the mechanisms underlying the SNP-mediated modulation of ADAM17 expression and the inflammatory response, which ultimately contributed to the development of sepsis.

ADAM17, which is also recognized as tumor necrosis factor alpha-converting enzyme (TACE), mediates inflammatory responses through the ectodomain shedding of pro-inflammatory cytokines in the transmembrane [30, 31]. The genomic deletion or pharmacologic inhibitor of ADAM17 in neutrophils and leukocytes results in evident resistance against LPS-induced endotoxemia and rescues mice from lethal septic shock [13, 14]. It is undisputed that ADAM17 plays an important role in the process of sepsis. Our previous study indicated that ADAM17 expression is significantly increased in severe septic patients compared with mild sepsis cases [11]. Our results obtained in this study showed that the expression of ADAM17 was significantly higher in the MODS subgroup compared with the non-MODS subgroup. ADAM17 expression was significantly decreased in the sepsis patients who survived during the 28-day period compared with the non-surviving patients. These results indicated that ADAM17 might exert a significant effect on the progression of sepsis and might also serve as an indicator of disease severity. Many studies on inflammatory diseases have demonstrated that ADAM17 polymorphisms influence the expression of ADAM17 mRNA via potential allele-specific transcription factor-binding sites. A recent study revealed that the ADAM17 m1254 A>G polymorphism is located at a binding site for the transcription factor HNF1A/B [32]. Another study suggested that the ADAM17 i33708 A>G polymorphism is located at a binding site for hepatocyte nuclear factor-2 (FOXA2), and available evidence indicates a regulatory role for the ADAM17 i62781 G>T polymorphism in the expression of the ADAM17 gene [33, 34]. Moreover, it has been reported that the ADAM17 -172GA/GG genotype is related to higher ADAM17 expression, which results in increased susceptibility to human abdominal aortic aneurysm [35]. In the present study, PBMCs with -172AG/GG genotypes exhibited a significantly higher expression of ADAM17 and inflammatory cytokines than those with AA genotype upon LPS stimulation, while these differences were not observed without LPS stimulation. These results were consistent with our previous study that the ADAM17 expression was significantly increased in sepsis patients with -172GA/GG genotypes compared to those with the AA genotype, while significantly different expression of ADAM17 was not found between the healthy controls with these genotypes, which further demonstrated that -172 A-to-G mutation contributed to the progression of sepsis.
rather than the occurrence of sepsis. Besides, our results show a significant increase in production of ADAM17 protein and TNF-α, IL-1β and IL-6 at 6 and 12 hours, and the TNF-α production reach a peak around 6-12 hours in consistent with ADAM17 protein production around 6-12 hours. Based on these results, we inferred that the ADAM17 SNP upregulates ADAM17 expression and the inflammatory response via the specific binding of transcriptional enhancers or other regulatory elements to the promoter region of ADAM17, which ultimately results in inflammatory cytokines production and sepsis progression. In addition, it was interesting that the sepsis-associated risk allele of -172G was closely associated with increased expression of EGR1 either in sepsis patients or LPS-stimulated PBMCs. We speculate that the -172 A-to-G mutation causes up-regulation in sepsis-associated inflammatory responses via activation of EGR1/ADAM17 axis, which may in return contributes to the EGR1 expression.

EGR1, a member of the early gene family, is an 80-kD transcription factor that preferentially binds to the GC-rich sequence 5'-GGGGGGCCG-3' in DNA in a zinc-dependent manner [36, 37]. In inflammation-related diseases, EGR1 has been implicated in the transcription of various genes, including TNF-α, M-CSF, TF, ICAM1, CD44, EGF-R, and TGF-β via its interaction with GC-rich regions, which play pivotal roles in various inflammatory-related diseases [38-47]. The ADAM17 rs12692386 is located within the gene promoter region and has binding sites for transcriptional regulatory elements. A bioinformatics analysis showed a conserved putative transcription factor-binding site for EGR1 in the 5'-UTR of human ADAM17. Our results showed that the presence of EGR1 significantly upregulated the expression of ADAM17 and substrates in LPS-stimulated cells, whereas these effects were completely abrogated by EGR1 knockdown. Thus, we speculated that EGR1 is an upstream regulator of the ADAM17 gene via allele-specific binding to the promoter region, and this binding is affected by the ADAM17 SNP. The ChiP-seq analysis results validated the binding of EGR1 to the ADAM17 promoter. No significant differences in luciferase reporter activity were observed between pGL3-A-Control and pGL3-G-Control groups, which might be attributed to the low expression of EGR1 and lower binding with ADAM17 gene promoter. However, the -172 A-to-G mutation results in higher luciferase reporter activities in presence of EGR1 overexpression, which further confirmed that ADAM17 A>G at the -172 position upregulated the affinity of EGR1 to the ADAM17 promoter region. These results provide strong evidence showing that the G allele at the -172 position of the ADAM17 promoter has higher binding affinity for EGR1 than the A allele and thus appears to play a pivotal role in enhancing ADAM17 promoter activity and upregulating ADAM17 transcription.

In this case-control study, we confirmed that the ADAM17 -172A>G polymorphism is associated with susceptibility to the progression of sepsis in consistent with our previous study. The further in vitro experiments of the molecular mechanism showed that this variant of ADAM17 can influence ADAM17 transcription via altering the binding affinity of EGR1 to the ADAM17 promoter region, ultimately causing increased production of pro-inflammatory cytokines and susceptibility to the disease severity of sepsis. Based on our results, carriers of the ADAM17 -172AG/GG genotype exhibit a worse prognosis. Moreover, the in vitro experiments revealed that EGR1 silencing resulted in decreased expression of cytokines and a lower cell apoptosis rate compared with the LPS group. Additionally, we found that the inhibition of EGR1 can reduce the inflammatory response and improve the survival of LPS-induced endotoxemia mice, which was consistent with our previous study [48]. However, another study reported that Egr-1 deficiency via gene knock-out did not positively affect survival and plasma levels of TNF in endotoxemic mice [49]. We speculate that several reasons might contribute to these contradictory results. The different methods with EGR1 inhibitor or gene knock-out for the blockade of EGR1 may leading to different impact of EGR1 deficiency on inflammatory responses in endotoxemic mice. In line with functional differences between members of the EGR family, the constitutive EGR2 knock-out is lethal. With regard to EGR1, mice lacking EGR1 exhibited reduced body size, sterility associated with alterations of the pituitary-gonadal axis as well as axial myopia [50-52], which may influence the effect of EGR1 deficiency on systemic inflammatory response induced by sepsis. Our result indicated that the application of EGR1 inhibitor in a short time may confer more benefit and safety in treatment for septic mice. Furthermore, because the inflammatory system is vast and complex, the EGR1 deficiency might result in different production of pro-inflammatory cytokines with small set of experimental samples. Therefore, these data need further validation. Overall, our study provides evidence indicating that the ADAM17 polymorphism is significantly associated with the progression of sepsis, and this association might aid the early identification and intervention of patients at risk for developing severe sepsis or septic shock. In addition, our exploration of the mechanism of susceptibility loci identified EGR1 as an important therapeutic target of sepsis.

Several limitations of this study should be mentioned. First, although inclusion and exclusion criteria were established to achieve greater sample homogeneity, we cannot preclude the possibility of unknown potential confounders, such as the pre-existing conditions of the patients with sepsis, which might affect the genetic results and observations in this study. Second, all the subjects enrolled in this study belonged to the Chinese Han population, and a larger sample and multiethnic population are required to analyze the heterogeneity of the research results. In addition, though this study focused on the correlation between ADAM17 gene
polymorphism and the progress of sepsis rather than the occurrence, the statistically significant differences in age and sex ratio were existed between the control group and the sepsis group, may also resulting in the imbalance of clinical baseline between the two groups, that was hard to excluded. Also, in animal experiments, the sampling time is single, and gene knockout mice are preferred to verify the hypothesis of this study.

Conclusions

In this study, we confirm that the ADAM17 -172A>G polymorphism confers susceptibility to the development of sepsis and poor prognosis. Carriers of the G allele exhibit higher expression levels of ADAM17 mRNA and inflammatory factors. In addition, EGR1 acts as a transcription factor targeting the 5'-UTR of the ADAM17 gene, and the -172A>G variation upregulates ADAM17 expression by altering this binding site and thereby leads to progression of the inflammatory response and sepsis (Fig. 6).

List Of Abbreviations

ADAM17: A disintegrin and metalloproteinase 17; EGR1: Early growth response 1; SNP: Single-nucleotide polymorphism; ChIP-qPCR: Chromatin immunoprecipitation-quantitative Polymerase Chain Reaction; RIPA: Radio-Immunoprecipitation Assay; ELISA: Enzyme-linked immunosorbent assay; TNF-a: Tumor necrosis factor alpha; IL-1β: Interleukin-1 beta; IL-6: Interleukin-6; VCAM-1: vascular cell adhesion molecule-1; ICAM1: intercellular cell adhesion molecule-1; APACHEII: acute physiology and chronic health evaluation II; cDNA: complementary deoxyribonucleic acid; PBMC: peripheral blood mononuclear cell; THP-1: Human acute monocytic leukemia cell line; RAW264.7 cell: mouse leukemia cells of monocyte macrophage; HUVECs: human umbilical vascular endothelial cells; HEK293T: human embryonic kidney cells; Ad-EGR1: adenoviruses containing EGR1; As-ODN: EGR1 antisense oligonucleotide; S-ODN: EGR1 sense ODN; LPS: Lipopolysaccharides; SP1: specificity protein 1; AP2α :TFAP2A; EGF-R: endothelial growth factor-receptor; TGF-β: Transforming growth factor.

Declarations

Ethics approval and consent to participate:

All experiments on human subjects were conducted in accordance with the Declaration of Helsinki. This study was approved by the Ethical Committee of the Affiliated Hospital of Guangdong Medical University, the Second Affiliated Hospital of Guangdong Medical University, the Central Hospital of Wuhan and the Second Affiliated Hospital of Harbin Medical University, and written informed consent was obtained from all the healthy volunteers and patients.

Consent for publication:

Not applicable

Availability of data and materials:

All data generated or analysed during this study are included in this published article.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This work was supported by the Natural Science Foundation of Guangdong Province (2019A1515010933; 2020A1515010109), the Novel Coronavirus Infection Prevention technology and product project of Zhanjiang City (2020E01007), the Science and Technology Project of Jieyang City (xgfy021), the National Nature Science Foundation of China (81772048 and 81671181) and the Fund of Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang)(ZJW-2019-007).
Authors' contributions

YS, JH and LC conceived and designed the experiments, and participated in its design and coordination and helped to draft the manuscript and revise the manuscript. YS, WZ and TZ collected the samples and clinical data, performed the experiments and the statistical analysis and drafted the manuscript. FL, YH, LL, YC, NW, HC and FC collected the samples and clinical data and helped to perform the experiments. All authors read and approved the final manuscript.

Acknowledgements:

Not applicable

References

1. Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851.
3. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729-733.
4. Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res. 2013;71:19-22.
5. Yan I, Schwarz J, Lucke K, et al. ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Ralpha from the cell surface of leukocytes during inflammatory responses. J Leukoc Biol. 2016;99(5):749-760.
6. Garton KJ, Gough PJ, Philalay J, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem. 2003;278(39):37459-37464.
7. Scheller J, Chalaris A, Garbers C, et al. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32(8):380-387.
8. Mishra HK, Ma J, Walcheck B. Ectodomain Shedding by ADAM17: Its Role in Neutrophil Recruitment and the Impairment of This Process during Sepsis. Front Cell Infect Microbiol. 2017;7:138.
9. Dreymueller D, Martin C, Kogel T, et al. Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide. EMBO Mol Med. 2012;4(5):412-423.
10. Kermarrec N, Selloum S, Plantefeve G, et al. Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha-converting enzyme cleavage. Crit Care Med. 2005;33(6):1359-1364.
11. Shao Y, He J, Chen F, et al. Association Study Between Promoter Polymorphisms of ADAM17 and Progression of Sepsis. Cell Physiol Biochem. 2016;39(4):1247-1261.
12. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370(6486):218-220.
13. Horiuchi K, Kimura T, Miyamoto T, et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol. 2007;179(5):2686-2689.
14. Mishra HK, Johnson TJ, Seelig DM, et al. Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis. J Leukoc Biol. 2016;100(5):999-1004.
15. Li Y, Cui LL, Li QQ, et al. Association between ADAM17 promoter polymorphisms and ischemic stroke in a Chinese population. Journal of atherosclerosis and thrombosis. 2014;21(8):878-893.
16. Feng Q, Deng Y, Yang X, et al. Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-beta/SMAD3 signaling pathway. Eur J Pediatr. 2016;175(5):705-713.
17. Morange PE, Tregouet DA, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med (Berl). 2008;86(10):1153-1161.
18. Sukhatme VP. Early transcriptional events in cell growth: the Egr family. J Am Soc Nephrol. 1990;1(6):859-866.
19. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol. 1995;50:191-224.
20. Shin SY, Kim JH, Baker A, et al. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol Cancer Res. 2010;8(4):507-519.

21. Nishi H, Nishi KH, Johnson AC. Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res. 2002;62(3):827-834.

22. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science. 1996;271(5254):1427-1431.

23. Shi L, Kishore R, McMullen MR, Nagy LE. Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1. Am J Physiol Cell Physiol. 2002;282(6):C1205-1211.

24. Pawlinski R, Pedersen B, Kehrle B, et al. Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood. 2003;101(10):3940-3947.

25. Coleman DL, Bartiss AH, Sukhatme VP, et al. Lipopolysaccharide induces Egr-1 mRNA and protein in murine peritoneal macrophages. J Immunol. 1992;149(9):3045-3051.

26. Shan J, Dudenhausen E, Kilberg MS. Induction of early growth response gene 1 (EGR1) by endoplasmic reticulum stress is mediated by the extracellular regulated kinase (ERK) arm of the MAPK pathways. Biochim Biophys Acta Mol Cell Res. 2019;1866(3):371-381.

27. Ngiam N, Post M, Kavanagh BP: Early growth response factor-1 in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1089-1091.

28. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41(2):580-637.

29. Zhang Y, Shi G, Zheng J, et al. The protective effect of Egr-1 antisense oligodeoxyribonucleotide on myocardial injury induced by ischemia-reperfusion and hypoxia-reoxygenation. Cell Physiol Biochem. 2008;22(5-6):645-652.

30. Lambrecht BN, Vanderkerken M, Hammad H. The emerging role of ADAM metalloproteinases in immunity. Nat Rev Immunol. 2018;18(12):745-758.

31. Grotzinger J, Lorenzen I, Dusterhoft S. Molecular insights into the multilayered regulation of ADAM17: The role of the extracellular region. Biochim Biophys Acta Acta Mol Res. 2017;1864(11 Pt B):2088-2095.

32. Stride A, Ellard S, Clark P, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes care. 2005;28(7):1751-1756.

33. Wolfrum C, Shih DQ, Kuwajima S, Norris AW, Kahn CR, Stoffel M. Role of Foxa-2 in adipocyte metabolism and differentiation. J Clin Invest. 2003;112(3):345-356.

34. Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet. 2007;39(10):1202-1207.

35. Li Y, Yang C, Ma G, et al. Analysis of ADAM17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm. Cell Physiol Biochem. 2014;33(5):1426-1438.

36. Wagner M, Schmelz K, Dorken B, Tamm I. Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer. 2008;122(6):1278-1287.

37. Gashler AL, Swaminathan S, Sukhatme VP. A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1. Mol Cell Biol. 1993;13(8):4556-4571.

38. Katz S, Zsiros V, Docioti N, Kiss AL. Inflammation-Induced Epithelial-to-Mesenchymal Transition and GM-CSF Treatment Stimulate Mesenteric Mesothelial Cells to Transdifferentiate into Macrophages. Inflammation. 2018;41(5):1825-1834.

39. Krishnaraju K, Hoffman B, Liebermann DA. The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells. Blood. 1998;92(6):1957-1966.

40. Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B. The zinc finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol Cell Biol. 1995;15(10):5499-5507.

41. Cui MZ, Parry GC, Oeth P, et al. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem. 1996;271(5):2731-2739.

42. Bea F, Puolakkainen MH, McMillen T, et al. Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res. 2003;92(4):394-401.

43. Maltzman JS, Carmen JA, Monroe JG. Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1. J Exp Med. 1996;183(4):1747-1759.

44. Ghatak S, Markwald RR, Hascall VC, et al. Transforming growth factor beta1 (TGFbeta1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts. J Biol Chem. 2017;
292(25):10465-10489.

45. Alagappan D, Balan M, Jiang Y, et al. Egr-1 is a critical regulator of EGF-receptor-mediated expansion of subventricular zone neural stem cells and progenitors during recovery from hypoxia-hypoglycemia. ASN Neuro. 2013;5(3):183-193.

46. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13(2):115-124.

47. Zhang M, Liao Y, Lonnerdal B. EGR-1 is an active transcription factor in TGF-beta2-mediated small intestinal cell differentiation. J Nutr Biochem. 2016;37:101-108.

48. Chen F, Wang Y, Zhang W, et al. A Functional Polymorphism-Mediated Disruption of EGR1/ADAM10 Pathway Confers the Risk of Sepsis Progression. mBio. 2019 Aug 6;10(4):e01663-19.

49. Pawlinski R, Pedersen B, Kehrle B, et al. Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood. 2003 May 15;101(10):3940-7.

50. Beckmann AM, Wilce PA. Egr transcription factors in the nervous system. Neurochem Int. 1997 Oct;31(4):477-510; discussion 517-6.

51. Topilko P, Schneider-Maunoury S, Levi G, et al. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol Endocrinol. 1998 Jan;12(1):107-22.

52. Schippert R, Burkhardt E, Feldkaemper M, Schaeffel F. Relative axial myopia in Egr-1 (ZENK) knockout mice. Invest Ophthalmol Vis Sci. 2007 Jan;48(1):11-7.

### Tables

**Table 1: Clinical characteristics of sepsis patients and healthy controls.**
| Variable                              | Sepsis subtype n=181 | Severe sepsis n=368 | Septic shock n=354 | Healthy controls n=1150 |
|--------------------------------------|----------------------|---------------------|---------------------|-------------------------|
| **Demographics**                     |                      |                     |                     |                         |
| Age, years, mean ± SD                | 60.1±15.0            | 61.0±18.5           | 59.9±19.1           | 48.1±15.2               |
| Male/female, number                  | 102/79               | 281/87              | 234/120             | 712/438                 |
| **Source of infection, no./total no. (%)** |                      |                     |                     |                         |
| Respiratory tract infection          | 81/181(43.2)         | 264/368(71.7)       | 241/354(68.1)       | N.A                     |
| Brain                                | 7/181(3.9)           | 16/368(4.3)         | 8/354(2.3)          | N.A                     |
| Bloodsteam infection                 | 17/181(9.4)          | 22/368(6.0)         | 28/354(7.9)         | N.A                     |
| Urinary tract infection              | 40/181(22.1)         | 14/368(3.8)         | 18/354(5.1)         | N.A                     |
| Catheter-associated infection        | 4/181(2.2)           | 5/368(1.4)          | 5/354(1.4)          | N.A                     |
| Wound infection                      | 6/181(3.3)           | 11/368(3.0)         | 9/354(2.5)          | N.A                     |
| Abdominal infection                  | 33/181(18.2)         | 38/368(10.3)        | 57/354(16.1)        | N.A                     |
| Others                               | 6/181(3.3)           | 11/368(3.0)         | 12/354(3.9)         | N.A                     |
| **Identified pathogen, no./total no. (%)** |                      |                     |                     |                         |
| Gram-positive(G+)                    | 20/181(11.1)         | 56/368(15.2)        | 33/354(9.3)         | N.A                     |
| Gram-negative(G-)                    | 67/181(37.0)         | 102/368(27.7)       | 127/354(35.9)       | N.A                     |
| Mixed Gram-negative and -positive    | 27/181(14.9)         | 47/368(12.8)        | 28/354(7.9)         | N.A                     |
| Fungus                               | 35/181(19.4)         | 18/368(4.9)         | 60/354(17.0)        | N.A                     |
| Polymicrobial                        | 18/181(9.9)          | 68/368(18.5)        | 23/354(6.5)         | N.A                     |
| Negative blood culture               | 158/181(87.3)        | 168/368(45.7)       | 209/354(59.0)       | N.A                     |
| **Pathogenic bacteria, no./total no. (%)** |                      |                     |                     |                         |
| Acinetobacter baumannii             | 58/181(32.0)         | 70/368(19.0)        | 109/354(30.8)       | N.A                     |
| Moniliaalbican                       | 32/181(17.7)         | 16/368(4.3)         | 37/354(10.5)        | N.A                     |
| Yeast sample sporphyte               | 8/181(4.4)           | 35/368(9.5)         | 16/354(4.5)         | N.A                     |
| Aspergillus                          | 2/181(1.1)           | 19/368(5.2)         | 17/354(4.8)         | N.A                     |
| Klebsiella pneumoniae                | 13/181(7.2)          | 19/368(5.2)         | 29/354(8.2)         | N.A                     |
| Pseudomonas aeruginosa               | 26/181(14.4)         | 57/368(15.5)        | 26/354(7.3)         | N.A                     |
| Staphylococcus aureus                | 13/181(7.1)          | 31/368(8.5)         | 35/354(23.2)        | N.A                     |
| Escherichia coli                     | 4/181(2.2)           | 67/368(18.2)        | 26/354(7.3)         | N.A                     |
| Others                               | 7/181(3.9)           | 72/368(19.6)        | 12/354(3.4)         | N.A                     |
| **APACHE II score, mean ± SD**       | 19.1±6.5             | 19.8±6.2            | 21.0±7.1            | N.A                     |

N.A: not applicable; APACHE II: Acute Physiology and Chronic Health Evaluation II; Continuous data are expressed as the mean ± SD.

Table 2: Genotype and allele frequencies distribution of the ADAM17 rs12692386 in the different sepsis status.
| rs12692386 | Sepsis subtype n=181 (%) | Severe sepsis n=368 (%) | Septic shock n=354 (%) | Severe sepsis & septic shock n=722(%) | P1 (P1*) | P2 (P2*) | P3 (P3*) |
|------------|--------------------------|--------------------------|-------------------------|---------------------------------------|---------|---------|---------|
| AA         | 128/181(70.7)            | 199/368(54.1)            | 204/354(58.6)           | 403/722(55.8)                         | 0.0002  | 0.0032  | 0.0003  |
| GA & GG    | 53/181(29.3)             | 169/368(45.9)            | 150/354(42.4)           | 319/722(42.2)                         | -       | -       | -       |
| A          | 300/362(82.9)            | 546/736(74.2)            | 543/708(76.7)           | 1089/1444(75.4)                      | 0.0013(0.0039) | 0.0193(0.0193) | 0.0026(0.0039) |
| G          | 62/362(17.1)             | 190/736(25.8)            | 165/708(23.3)           | 355/1444(24.6)                       | -       | -       | -       |

P1: sepsis subtype versus severe sepsis; P2: sepsis subtype versus septic shock; P3, sepsis subtype versus severe sepsis & septic shock. *False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamin-Hochberg method.

Table 3: Genotype and allele frequencies distribution of the ADAM17 rs12692386 in the cases and controls.

| Genotypes | Sepsis n=903 (%) | Control n=1150 (%) | P   | P*     | OR (95% CI) |
|-----------|------------------|--------------------|-----|--------|-------------|
| AA        | 531/903(58.8)    | 697/1150(60.6)     | 0.3043 | 0.5436 | -           |
| AG        | 327/903(36.2)    | 384/1150(33.4)     | -    | -      | -           |
| GG        | 45/903(5.0)      | 69/1150(6.0)       | -    | -      | -           |
| AA&AG     | 858/903(95.0)    | 1081/1150(94.0)    | 0.3181 | 0.5436 | 1.217(0.827, 1.791) |
| AG&GG     | 372/903(14.9)    | 453/1150(39.4)     | 0.4077 | 0.5436 | 1.078(0.902, 1.287) |
| A         | 1389/1806(76.9)  | 1778/2300(77.3)    | -    | -      | -           |
| G         | 417/1806(23.1)   | 522/2300(22.7)     | 0.7654 | 0.7654 | 0.978(0.845, 1.132) |

OR: odds ratio; 95% CI: 95% confidence interval. *False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamin-Hochberg method.

Table 4: Genotype and allele frequencies distribution between 28-day surviving and non-surviving sepsis patients.

| rs12692386 | Survivors n=751 (%) | Non-survivors n=152 (%) | P     | P*     | OR (95% CI) |
|------------|---------------------|-------------------------|-------|--------|-------------|
| AA         | 456/751(60.7)       | 75/152(49.3)            | 0.0178 | 0.0237 | -           |
| AG         | 262/751(34.9)       | 65/152(42.8)            | -     | -      | -           |
| GG         | 33/751(4.4)         | 12/152(7.9)             | -     | -      | -           |
| AA&AG      | 718/751(95.6)       | 140/152(92.1)           | 0.0705 | 0.0705 | 1.865(0.940, 3.700) |
| AG&GG      | 295/751(39.3)       | 77/152(50.7)            | 0.0094 | 0.0188 | 0.630(0.444, 0.894) |
| A          | 1174/1502(78.2)     | 215/304(70.7)           | -     | -      | -           |
| G          | 328/1502(21.8)      | 89/304(29.3)            | 0.0050 | 0.0188 | 1.482(1.125, 1.952) |
*False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamin-Hochberg method.

Figures

Figure 1

Impact of ADAM17 SNP on expression of ADAM17 and inflammatory factors. (a) The expression of ADAM17 in the 80 sepsis cases separated by the number of organ failure and patients' 28-day mortality. (b) PBMCs of 36 healthy controls were isolated and divided into Control group (n=18) and LPS group (800 ng/mL, 6 h, n=18). The ADAM17 mRNA expression in PBMCs of Control and LPS group; The ADAM17 rs12692386 polymorphism of these 36 subjects were genotyped and divided into AA and AG/GG group (n=12 for AA carriers, and n=6 for AG/GG carriers in LPS group; n=13 for AA carriers, and n=5 for AG/GG carriers in Control group). The ADAM17 mRNA expression in these two groups with different rs12692386 genotypes. (c) The inflammatory cytokines (IL-6 and TNF-α) levels in these two groups with different rs12692386 genotypes. Error bar represent standard error of the mean (SD). *P<0.05, **P<0.01, and ***P<0.001.
Figure 2

Expression of predicted transcription factors in sepsis. (a) Bioinformatics analysis of binding of transcription factors to the promoter region of ADAM17 around the -172 position; (b) RT-qPCR analysis of transcription factor (EGR1, AP2α, and SP1) expression in HUVECs and RAW264.7 cells with increasing doses of LPS (0, 100, 500, 1000, 5000 ng/mL) for 6 hours; (c) Western blot analysis of transcription factors and ADAM17 expressions in HUVECs treated with LPS (1000 ng/mL for 6 hours). ***P<0.001 vs. control group; (d) Western blot analysis of ADAM17 protein production in HUVECs with an increasing duration of LPS (1000 ng/mL); (e) RT-qPCR analysis of EGR1 and ADAM17 mRNA expression in HUVECs with an increasing duration of LPS (1000 ng/mL); (f) Concentration of cytokines (TNF-α, IL-1-β and IL-6) in HUVECs with an increase stimulation time of LPS (1000 ng/mL); (g) RT-qPCR analysis of EGR1 expression in PBMCs isolated from 33 sepsis patients and 45 healthy controls; (h) RT-qPCR analysis of EGR1 expression in PBMCs isolated from 36 healthy controls (n=18 for Control group and n=18 for LPS group). PBMCs were stimulated with LPS at a dose of 800 ng/mL for 6 hours; (i) RT-qPCR analysis of EGR1 expression in PBMCs with different genotypes isolated from 33 sepsis patients (n=17 for AA carriers, and n=16 for AG/GG carriers). (j) RT-qPCR analysis of EGR1 expression in LPS-induced PBMCs with different genotypes. (n=12 for AA carriers, and n=6 for AG/GG carriers). Error bar represent standard error of the mean (SD). *P<0.05, **P<0.01, and ***P<0.001.
Cellular schematic of the molecular mechanism of ADAM17 SNP-mediated EGR1 modulation on ADAM17 expression in the progression of sepsis. The A to G mutation of ADAM17 -172A>G polymorphism increased the binding affinity of transcription factor EGR1 to ADAM17 promoter region, which transcriptionally elevated the expression of ADAM17 and ultimately exacerbated sepsis to severe sepsis/septic shock via increasing the cleavage activity of ADAM17 to substrates, including pro-inflammatory (IL-1β, IL-6, TNF-α).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile5.pdf
- Additionalfile6.pdf
- Additionalfile7.pdf